StemCell Therapy

Peter J. Embi, MD1,2, Matthew E. Levy, PhD3, Allison L. Naleway, PhD4, Palak Patel, MBBS5, Manjusha Gaglani, MBBS6, Karthik Natarajan, PhD7,8, Kristin Dascomb, MD, PhD9, Toan C. Ong, PhD10, Nicola P. Klein, MD, PhD11, I-Chia Liao, MPH6, Shaun J. Grannis, MD2,12, Jungmi Han7, Edward Stenehjem, MD9, Margaret M. Dunne, MSc3, Ned Lewis, MPH11, Stephanie A. Irving, MHS4, Suchitra Rao, MBBS10, Charlene McEvoy, MD13, Catherine H. Bozio, PhD5, Kempapura Murthy, MBBS6, Brian E. Dixon, PhD12,14, Nancy Grisel, MPP9, Duck-Hye Yang, PhD3, Kristin Goddard, MPH11, Anupam B. Kharbanda, MD15, Sue Reynolds, PhD5, Chandni Raiyani, MPH6, William F. Fadel, PhD12,14, Julie Arndorfer, MPH9, Elizabeth A. Rowley, DrPH3, Bruce Fireman, MA11, Jill Ferdinands, PhD5, Nimish R. Valvi, DrPH12, Sarah W. Ball, ScD3, Ousseny Zerbo, PhD11, Eric P. Griggs, MPH5, Patrick K. Mitchell, ScD3, Rachael M. Porter, MPH5, Salome A. Kiduko, MPH3, Lenee Blanton, MPH5, Yan Zhuang, PhD3, Andrea Steffens, MPH5, Sarah E. Reese, PhD3, Natalie Olson, MPH5, Jeremiah Williams, MPH5, Monica Dickerson, MPH5, Meredith McMorrow, MD5, Stephanie J. Schrag, DPhil5, Jennifer R. Verani, MD5, Alicia M. Fry, MD5, Eduardo Azziz-Baumgartner, MD5, Michelle A. Barron, MD10, Mark G. Thompson, PhD5 and Malini B. DeSilva, MD13

1Regenstrief Institute, Indianapolis, Indiana; 2Indiana University School of Medicine, Indianapolis, Indiana; 3Westat, Rockville, Maryland; 4Center for Health Research, Kaiser Permanente Northwest, Portland, Oregon; 5CDC COVID-19 Response Team; 6Baylor Scott & White Health, Texas A&M University College of Medicine, Temple, Texas; 7Department of Biomedical Informatics, Columbia University, New York, New York; 8New York Presbyterian Hospital, New York, New York; 9Division of Infectious Diseases and Clinical Epidemiology, Intermountain Healthcare, Salt Lake City, Utah; 10School of Medicine, University of Colorado, Anschutz Medical Campus, Aurora, Colorado; 11Kaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California, Oakland, California; 12Center for Biomedical Informatics, Regenstrief Institute, Indianapolis, Indiana; 13HealthPartners Institute, Minneapolis, Minnesota; 14Fairbanks School of Public Health, Indiana University, Indianapolis, Indiana; 15Children's Minnesota, Minneapolis, Minnesota.

Corresponding author Peter J. Embi, pembi@regenstrief.org.

All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Allison L. Naleway reports institutional support from Pfizer outside the submitted work. Anupam B. Kharbanda reports institutional support through HealthPartners to Children's Minnesota for VISION. Charlene McEvoy reports institutional support from AstraZeneca for the AZD1222 COVID-19 vaccine trial. Jill Ferdinands reports travel support from Institute for Influenza Epidemiology, funded in part by Sanofi Pasteur. Nicola P. Klein reports institutional support from Pfizer for COVID-19 vaccine clinical trials and institutional support from Pfizer, Merck, GlaxoSmithKline, Sanofi Pasteur, and Protein Sciences (now Sanofi Pasteur) outside the submitted work. Suchitra Rao reports grant support from GlaxoSmithKline and Biofire Diagnostics. No other potential conflicts of interest were disclosed.

Read more:
mRNA COVID-19 Vaccine Effectiveness in the Immunocompromised - Medscape

This entry was posted on January 30, 2022 at 1:50 am and is filed under Stem Cell Negative. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |